Payment overview · 2025
General Payments
$838.23
26 reported records · 7 companies
Healthcare provider profile · identity verified
Richard P Senzer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WASHINGTON, NJ · NPI 1508961772
Verified facts
What the public records show
CMS Open Payments records show Richard P Senzer, M.D. received $838.23 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 62.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $525.53 | 62.7% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $126.60 | 15.1% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.90 | 8.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.97 | 6.7% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $28.73 | 3.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.91 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.59 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $838.23 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $265.30 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $224.90 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $222.19 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $108.55 | 6 | 2025 |
Source payment records
|
|||||
| ANDEXXA Normalized: andexxa |
Biological | AstraZeneca Pharmaceuticals LP | $100.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $90.19 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.90 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.97 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.50 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $28.73 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
81 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 293 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 45 |
| Eliquis | Apixaban | 226 | 20 |
| Metformin Hcl | Metformin Hcl | 219 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 26 |
| Gabapentin | Gabapentin | 140 | 24 |
| Alprazolam | Alprazolam | 138 | 33 |
| Donepezil Hcl | Donepezil Hcl | 137 | 14 |
| Trazodone Hcl | Trazodone Hcl | 131 | 15 |
| Sertraline Hcl | Sertraline Hcl | 127 | 19 |
| Losartan Potassium | Losartan Potassium | 121 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 15 |
| Famotidine | Famotidine | 114 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 102 | suppressed |
| Memantine Hcl | Memantine Hcl | 100 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 20 |
| Lisinopril | Lisinopril | 87 | 20 |
| Trulicity | Dulaglutide | 81 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 14 |
| Divalproex Sodium | Divalproex Sodium | 73 | suppressed |
| Furosemide | Furosemide | 73 | 20 |
| Mirtazapine | Mirtazapine | 68 | 12 |
| Tramadol Hcl | Tramadol Hcl | 68 | suppressed |
| Glimepiride | Glimepiride | 67 | 13 |
| Buspirone Hcl | Buspirone Hcl | 65 | 11 |
| Metformin Hcl Er | Metformin Hcl | 63 | 13 |
| Montelukast Sodium | Montelukast Sodium | 63 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 62 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 59 | suppressed |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Potassium Chloride | Potassium Chloride | 58 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 21 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 50 | 50 |
| Azithromycin | Azithromycin | 47 | 34 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 26 |
| Baclofen | Baclofen | 45 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 44 | 11 |
| Atenolol | Atenolol | 41 | suppressed |
| Omeprazole | Omeprazole | 41 | 14 |
| Allopurinol | Allopurinol | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 11 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Simvastatin | Simvastatin | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 17 |
| Clonazepam | Clonazepam | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $838.23 · 26 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ANDEXXA, AUSTEDO XR, BREZTRI, CAPLYTA, FARXIGA, Kerendia, MOUNJARO, Ozempic, REXULTI, Rybelsus, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error